Eligi
Med
Ensayos clínicos
Suscripción
Sobre EligiMed
Ensayos Clínicos de Urología | EligiMed
Ensayos clínicos
8.676 ensayos encontrados
Completado
Fase 2
ClinicalTrials.gov
A Phase II Efficacy And Safety Study Of Sunitinib Malate (SU011248) Administered In A Continuous Daily Regimen In Patients With Advanced (First-Line) Renal Cell Cancer
INTERVENTIONAL
Inicio: 1 de sept de 2006
ID: NCT00338884
Reclutando
Fase 3
ClinicalTrials.gov
A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NMIBC) and Susceptible FGFR Alterations
INTERVENTIONAL
Inicio: 18 de abr de 2024
ID: NCT06319820
Aún no recluta
ClinicalTrials.gov
Comprehensive Program for Hereditary Transthyretin Amyloidosis
OBSERVATIONAL
Inicio: 1 de oct de 2025
ID: NCT07213297
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Apalutamide Plus Androgen Deprivation Therapy (ADT) Versus ADT in Subjects With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
INTERVENTIONAL
Inicio: 27 de nov de 2015
ID: NCT02489318
Terminado
Fase 3
ClinicalTrials.gov
A Phase III, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study of Atezolizumab (Anti-PD-L1 Antibody) as Adjuvant Therapy in Patients With Renal Cell Carcinoma at High Risk of Developing Metastasis Following Nephrectomy
INTERVENTIONAL
Inicio: 3 de ene de 2017
ID: NCT03024996
Terminado
Fase 3
ClinicalTrials.gov
A Phase 3, Randomized, Double-blind Trial of Nivolumab in Combination With Intravesical BCG Versus Standard of Care BCG Alone in Participants With High-risk Non-muscle Invasive Bladder Cancer That Is Persistent or Recurrent After Treatment With BCG
INTERVENTIONAL
Inicio: 15 de ene de 2020
ID: NCT04149574
Completado
ClinicalTrials.gov
Mortality and Neurologic Complications Associated With Rapid Versus Slow Correction of Hyponatremia
OBSERVATIONAL
Inicio: 1 de mar de 2024
ID: NCT06675591
Completado
Fase 3
ClinicalTrials.gov
A Phase 3, Randomized, Controlled Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma That Has Progressed After Prior VEGFR Tyrosine Kinase Inhibitor Therapy
INTERVENTIONAL
Inicio: 1 de jun de 2013
ID: NCT01865747
Completado
Fase 3
ClinicalTrials.gov
A Phase III Randomized Study of BAY43-9006 in Patients With Unresectable and/or Metastatic Renal Cell Cancer.
INTERVENTIONAL
Inicio: 1 de nov de 2003
ID: NCT00073307
Desconocido
ClinicalTrials.gov
Virtual Bladder Training for Overactive Bladder Syndrome in Women. Which Symptom Responds Better?
INTERVENTIONAL
Inicio: 1 de may de 2022
ID: NCT05493748
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Phase III, Double-blind, Multicenter, Randomized Study of Atezolizumab (Anti-PDL1 Antibody) Versus Placebo as Adjuvant Therapy in Patients With High-risk Muscle-invasive Bladder Cancer Who Are ctDNA Positive Following Cystectomy
INTERVENTIONAL
Inicio: 3 de may de 2021
ID: NCT04660344
Reclutando
Fase 2
ClinicalTrials.gov
A Phase 2 Multi-Cohort, Open-Label, Multi-Center Clinical Study Evaluating the Efficacy and Safety of Disitamab Vedotin (RC48-ADC) Alone or in Combination With Pembrolizumab in Subjects With Locally-Advanced Unresectable or Metastatic Urothelial Carcinoma That Expresses HER2
INTERVENTIONAL
Inicio: 3 de may de 2022
ID: NCT04879329
Completado
Fase 3
ClinicalTrials.gov
Affirm: A Multinational Phase 3, Randomized, Double-blind, Placebo-controlled Efficacy And Safety Study Of Oral Mdv3100 In Patients With Progressive Castration-resistant Prostate Cancer Previously Treated With Docetaxel Based Chemotherapy
INTERVENTIONAL
Inicio: 30 de sept de 2009
ID: NCT00974311
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-641)
INTERVENTIONAL
Inicio: 28 de jul de 2019
ID: NCT03834493
Reclutando
Fase 2
ClinicalTrials.gov
Castration With Abiraterone 250 mg Without LHRH Analogs or Blockers in Patients With Prostate Cancer Requiring Hormonal Intensification (Multicenter Phase 2)
INTERVENTIONAL
Inicio: 1 de dic de 2025
ID: NCT07299292
Completado
Fase 3
ClinicalTrials.gov
Randomized, Open Label Multi-Center Study Comparing Cabazitaxel at 20 mg/m² and at 25 mg/m² Every 3 Weeks in Combination With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen
INTERVENTIONAL
Inicio: 1 de abr de 2011
ID: NCT01308580
Reclutando
Fase 3
ClinicalTrials.gov
A Randomised, Double-blind, Placebo-controlled, Phase III Study of Adjuvant Saruparib (AZD5305) in Patients With BRCAm Localised High-Risk Prostate Cancer Receiving Radiotherapy With Androgen Deprivation Therapy (EvoPAR-Prostate02).
INTERVENTIONAL
Inicio: 6 de ago de 2025
ID: NCT06952803
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Phase III, Open Label, Randomised, 3-Arm, Multi-Centre Study of Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic Papillary Renal Cell Carcinoma (SAMETA)
INTERVENTIONAL
Inicio: 28 de oct de 2021
ID: NCT05043090
Activo, no recluta
Fase 2
ClinicalTrials.gov
A Phase 2 Study to Evaluate Patient Reported Preference for Subcutaneous Pembrolizumab Coformulated With Hyaluronidase (MK-3475A) Over Intravenous Pembrolizumab Formulation in Participants With Multiple Tumor Types (MK-3475A-F11)
INTERVENTIONAL
Inicio: 26 de dic de 2023
ID: NCT06099782
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Phase 3b, Randomized, Double-blind Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Monotherapy for Patients With Previously Untreated Advanced Renal Cell Carcinoma and Intermediate- or Poor-Risk Factors
INTERVENTIONAL
Inicio: 21 de jun de 2019
ID: NCT03873402
Anterior
1
...
11
12
13
...
434
Siguiente
Filtros